Substituted Aryl Ether Inhibits RET Kinase for Lung Adenocarcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung adenocarcinoma with RET fusion proteins lack selective inhibitors, leading to inadequate therapeutic options for patients with RET fusion proteins, despite existing kinase inhibitors showing some inhibitory effects.
Innovation Solution
Development of substituted aryl ether derivatives with novel structures, designed to selectively inhibit RET kinase activity, which are synthesized and studied for their antitumor activity to treat diseases associated with abnormal cell proliferation and cancer metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors (Danusertib, Regorafenib, Gefitinib, Sunitinib) are used to treat RET fusion protein-positive lung adenocarcinoma, then some inhibitory effect on RET kinase is achieved, but the treatment lacks selectivity and adequate therapeutic efficacy
Solution Approach 1:
The patent applies local quality by designing specific substituent patterns at defined positions on the aryl ether core structure. Different substituents (R1-R6 groups) are strategically placed to optimize interactions with specific residues in the RET kinase binding pocket, thereby achieving selective inhibition of RET over other kinases while maintaining therapeutic efficacy
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types, positions, and steric/electronic properties on the aryl ether scaffold. This structure-activity relationship optimization enables fine-tuning of both selectivity and potency, transforming general kinase inhibitors into RET-selective agents
2Adaptability or versatility
If there are no selective RET inhibitors available, then existing multi-kinase inhibitors can be used as alternatives, but this results in inadequate therapeutic options and limited treatment effectiveness for RET fusion protein-positive patients
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor development into specific subcategories: aryl ether derivatives with particular substituent configurations targeted at RET kinase. This segmentation allows focused optimization of selectivity for RET while maintaining drug-like properties and therapeutic efficacy
Solution Approach 2:
The patent uses composite materials by combining the aryl ether core structure with diverse substituent groups (including heterocyclic, aromatic, and aliphatic moieties). This composite molecular architecture enables simultaneous achievement of selective RET binding and adequate therapeutic effect
Data Source
AI summary
The present invention relates to a compound having the following formula, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, preparation method thereof, pharmaceutical composition comprising the same and use of the compound in the manufacture of a medicament for preventing or treating tumor, wherein the substituents are as defined in the specification.